AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Increase in incidences of cancer worldwide and favorable reimbursement policies provided by manufacturers & insurance providers drive the growth of the market
PORTLAND, OR, UNITED STATES, January 28, 2025 /EINPresswire.com/ -- Allied Market Research published a report, titled, "Idiopathic Pulmonary Fibrosis Market by Drug Type (Nintedanib, and Pirfenidone) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2030." According to the report, the global Idiopathic Pulmonary Fibrosis Market Size was Valued at USD 3.12 billion in 2020 and is Projected to Garner USD 6.16 billion by 2030, registering a CAGR of 7.0% from 2021 to 2030.
The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.
𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐟𝐚𝐜𝐭𝐨𝐫𝐬 𝐝𝐫𝐢𝐯𝐢𝐧𝐠 𝐭𝐡𝐞 𝐈𝐝𝐢𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭?
Increase in incidences of cancer worldwide, favorable reimbursement policies provided by manufacturers & insurance providers, and rise in cigarette smoking drive the growth of the global idiopathic pulmonary fibrosis market. However, the unavailability of the proper treatment options restrains the market growth. On the other hand, rise in number of pipeline drugs and untapped potential in developing countries present new opportunities in the coming years.
𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐆𝐫𝐚𝐩𝐡𝐬 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬 𝐇𝐞𝐫𝐞: https://www.alliedmarketresearch.com/request-sample/4407
𝐓𝐨𝐩 𝐈𝐝𝐢𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Boehringer Ingelheim
• GNI Group Ltd
• F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
• Shiongi co Ltd
• Mission Therapeutics
• Biogen, Inc.
• Galapagos NV
• FibroGen, Inc.
𝐈𝐝𝐢𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐜𝐚𝐧 𝐛𝐞 𝐝𝐨𝐧𝐞 𝐛𝐚𝐬𝐞𝐝 𝐨𝐧 𝐬𝐞𝐯𝐞𝐫𝐚𝐥 𝐟𝐚𝐜𝐭𝐨𝐫𝐬, 𝐢𝐧𝐜𝐥𝐮𝐝𝐢𝐧𝐠:
Based on drug type, the pirfenidone segment accounted for the highest share in 2020, holding around three-fourths of the global idiopathic pulmonary fibrosis market, and is expected to continue its leadership status during the forecast period. Moreover, this segment is projected to manifest the highest CAGR of 7.2% from 2021 to 2030. This is due to rise in adoption of pirfenidone drugs such as Esbriet and Pirespa across the world. The research also analyzes the nintedanib segment.
Based on distribution channel, the retail pharmacies segment accounted for the highest share in 2020, contributing to nearly half of the global idiopathic pulmonary fibrosis market, and is estimated to continue its lead position during the forecast period. This is attributed to rapid increase in rate of idiopathic pulmonary fibrosis among the geriatric population, technological advancements, and lifestyle changes worldwide. However, the online providers segment is expected to portray the largest CAGR of 8.5% from 2021 to 2030. This is due to offers and discounts offered by providers and the availability of different types of drugs under a single platform.
Based on region, North America contributed to the highest market share in 2020, holding more than two-fifths of the global idiopathic pulmonary fibrosis market, and is projected to continue its lead in terms of revenue by 2030. This is attributed to high expenditure on R&D activities, presence of major players & their product availability, and well-established healthcare infrastructure in the region. However, Asia-Pacific is expected to manifest the fastest CAGR of 8.9% during the forecast period, owing to improvement in R&D facilities and rapidly developing economic conditions.
𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/purchase-enquiry/4407
Our Market Research Solution Provides You Answer to Below Mentioned Question:
• Which are the driving factors responsible for the growth of market?
• Which are the roadblock factors of this market?
• What are the new opportunities, by which market will grow in coming years?
• What are the trends of this market?
• Which are main factors responsible for new product launch?
• How big is the global & regional market in terms of revenue, sales and production?
• How far will the market grow in forecast period in terms of revenue, sales and production?
• Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
• How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
• Which region has more opportunities?
By Region Outlook
• North America
(U.S., Canada, Mexico)
• Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
• LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Contact Details:
David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
[email protected]
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
David Correa
Allied Market Research
+ +1 800-792-5285
email us here
Visit us on social media:
Facebook
X
LinkedIn
YouTube
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
